Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer

The treatment of cancer patients has been mainly followed using chemotherapy and it is a gold standard in improving prognosis and survival rate of patients. Oxaliplatin (OXA) is a third-platinum anti-cancer agent that reduces DNA synthesis in cancer cells to interfere with their growth and cell cycl...

Full description

Bibliographic Details
Authors: Hashemi, Mehrdad, Esbati, Nastaran, Rashidi, Mohsen, Gholami, Sadaf|||0000-0002-4319-3346, Raesi, Rasoul, Bidoki, Seyed Shahabadin, Goharrizi, Mohammad Ali Sheikh Beig, Motlagh, Yasamin Sadat Mousavi, Khorrami, Ramin, Tavakolpournegari, Alireza|||0000-0002-1555-7149, Nabavi, Noushin, Zou, Rongjun, Mohammadnahal, Leila|||0000-0002-0221-0381, Entezari, Maliheh, Taheriazam, Afshin, Hushmandi, Kiavash
Format: article
Publication Date:2024
Country:España
Institution:Universitat Autònoma de Barcelona
Repository:Dipòsit Digital de Documents de la UAB
Language:English
OAI Identifier:oai:ddd.uab.cat:311190
Online Access:https://ddd.uab.cat/record/311190
https://dx.doi.org/urn:doi:10.1016/j.tranon.2023.101846
Access Level:Open access
Keyword:Oxaliplatin
Cancer chemotherapy
Drug resistance
Molecular pathways
Colorectal cancer
id ES_fb81e7b4e2477403f4cf1b725efacb9c
oai_identifier_str oai:ddd.uab.cat:311190
network_acronym_str ES
network_name_str España
repository_id_str
spelling Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancerHashemi, MehrdadEsbati, NastaranRashidi, MohsenGholami, Sadaf|||0000-0002-4319-3346Raesi, RasoulBidoki, Seyed ShahabadinGoharrizi, Mohammad Ali Sheikh BeigMotlagh, Yasamin Sadat MousaviKhorrami, RaminTavakolpournegari, Alireza|||0000-0002-1555-7149Nabavi, NoushinZou, RongjunMohammadnahal, Leila|||0000-0002-0221-0381Entezari, MalihehTaheriazam, AfshinHushmandi, KiavashOxaliplatinCancer chemotherapyDrug resistanceMolecular pathwaysColorectal cancerThe treatment of cancer patients has been mainly followed using chemotherapy and it is a gold standard in improving prognosis and survival rate of patients. Oxaliplatin (OXA) is a third-platinum anti-cancer agent that reduces DNA synthesis in cancer cells to interfere with their growth and cell cycle progression. In spite of promising results of using OXA in cancer chemotherapy, the process of drug resistance has made some challenges. OXA is commonly applied in treatment of colorectal cancer (CRC) as a malignancy of gastrointestinal tract and when CRC cells increase their proliferation and metastasis, they can obtain resistance to OXA chemotherapy. A number of molecular factors such as CHK2, SIRT1, c-Myc, LATS2 and FOXC1 have been considered as regulators of OXA response in CRC cells. The non-coding RNAs are able to function as master regulator of other molecular pathways in modulating OXA resistance. There is a close association between molecular mechanisms such as apoptosis, autophagy, glycolysis and EMT with OXA resistance, so that apoptosis inhibition, pro-survival autophagy induction and stimulation of EMT and glycolysis can induce OXA resistance in CRC cells. A number of anti-tumor compounds including astragaloside IV, resveratrol and nobiletin are able to enhance OXA sensitivity in CRC cells. Nanoparticles for increasing potential of OXA in CRC suppression and reversing OXA resistance have been employed in cancer chemotherapy. These subjects are covered in this review article to shed light on molecular factors resulting in OXA resistance. 22024-01-0120242024-01-01Article de revisióhttp://purl.org/coar/resource_type/c_dcae04bcVoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/311190https://dx.doi.org/urn:doi:10.1016/j.tranon.2023.101846reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3111902026-06-06T12:50:31Z
dc.title.none.fl_str_mv Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer
title Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer
spellingShingle Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer
Hashemi, Mehrdad
Oxaliplatin
Cancer chemotherapy
Drug resistance
Molecular pathways
Colorectal cancer
title_short Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer
title_full Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer
title_fullStr Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer
title_full_unstemmed Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer
title_sort Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer
dc.creator.none.fl_str_mv Hashemi, Mehrdad
Esbati, Nastaran
Rashidi, Mohsen
Gholami, Sadaf|||0000-0002-4319-3346
Raesi, Rasoul
Bidoki, Seyed Shahabadin
Goharrizi, Mohammad Ali Sheikh Beig
Motlagh, Yasamin Sadat Mousavi
Khorrami, Ramin
Tavakolpournegari, Alireza|||0000-0002-1555-7149
Nabavi, Noushin
Zou, Rongjun
Mohammadnahal, Leila|||0000-0002-0221-0381
Entezari, Maliheh
Taheriazam, Afshin
Hushmandi, Kiavash
author Hashemi, Mehrdad
author_facet Hashemi, Mehrdad
Esbati, Nastaran
Rashidi, Mohsen
Gholami, Sadaf|||0000-0002-4319-3346
Raesi, Rasoul
Bidoki, Seyed Shahabadin
Goharrizi, Mohammad Ali Sheikh Beig
Motlagh, Yasamin Sadat Mousavi
Khorrami, Ramin
Tavakolpournegari, Alireza|||0000-0002-1555-7149
Nabavi, Noushin
Zou, Rongjun
Mohammadnahal, Leila|||0000-0002-0221-0381
Entezari, Maliheh
Taheriazam, Afshin
Hushmandi, Kiavash
author_role author
author2 Esbati, Nastaran
Rashidi, Mohsen
Gholami, Sadaf|||0000-0002-4319-3346
Raesi, Rasoul
Bidoki, Seyed Shahabadin
Goharrizi, Mohammad Ali Sheikh Beig
Motlagh, Yasamin Sadat Mousavi
Khorrami, Ramin
Tavakolpournegari, Alireza|||0000-0002-1555-7149
Nabavi, Noushin
Zou, Rongjun
Mohammadnahal, Leila|||0000-0002-0221-0381
Entezari, Maliheh
Taheriazam, Afshin
Hushmandi, Kiavash
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Oxaliplatin
Cancer chemotherapy
Drug resistance
Molecular pathways
Colorectal cancer
topic Oxaliplatin
Cancer chemotherapy
Drug resistance
Molecular pathways
Colorectal cancer
description The treatment of cancer patients has been mainly followed using chemotherapy and it is a gold standard in improving prognosis and survival rate of patients. Oxaliplatin (OXA) is a third-platinum anti-cancer agent that reduces DNA synthesis in cancer cells to interfere with their growth and cell cycle progression. In spite of promising results of using OXA in cancer chemotherapy, the process of drug resistance has made some challenges. OXA is commonly applied in treatment of colorectal cancer (CRC) as a malignancy of gastrointestinal tract and when CRC cells increase their proliferation and metastasis, they can obtain resistance to OXA chemotherapy. A number of molecular factors such as CHK2, SIRT1, c-Myc, LATS2 and FOXC1 have been considered as regulators of OXA response in CRC cells. The non-coding RNAs are able to function as master regulator of other molecular pathways in modulating OXA resistance. There is a close association between molecular mechanisms such as apoptosis, autophagy, glycolysis and EMT with OXA resistance, so that apoptosis inhibition, pro-survival autophagy induction and stimulation of EMT and glycolysis can induce OXA resistance in CRC cells. A number of anti-tumor compounds including astragaloside IV, resveratrol and nobiletin are able to enhance OXA sensitivity in CRC cells. Nanoparticles for increasing potential of OXA in CRC suppression and reversing OXA resistance have been employed in cancer chemotherapy. These subjects are covered in this review article to shed light on molecular factors resulting in OXA resistance.
publishDate 2024
dc.date.none.fl_str_mv 2
2024-01-01
2024
2024-01-01
dc.type.none.fl_str_mv Article de revisió
http://purl.org/coar/resource_type/c_dcae04bc
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/311190
https://dx.doi.org/urn:doi:10.1016/j.tranon.2023.101846
url https://ddd.uab.cat/record/311190
https://dx.doi.org/urn:doi:10.1016/j.tranon.2023.101846
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425335079010304
score 15,811543

Similar Items